Six reasons to invest in Living Cell Technologies

ALSIS 2012
A company on a mission

Cell based therapies to improve the lives of people with serious disease

IP: US, EU, world
GMP manufacture
Encapsulation
#2

**A lead product in late stage clinical development**

**DIABECCELL® for the treatment of unstable Type I Diabetes**

<table>
<thead>
<tr>
<th>Feature</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product</td>
<td>Encapsulated porcine islets</td>
</tr>
<tr>
<td>Target market</td>
<td>Unstable Type I diabetes – 1.6m patients</td>
</tr>
<tr>
<td>Product differentiator</td>
<td>β-cell replacement therapy without immunosuppression</td>
</tr>
<tr>
<td>Stage of development</td>
<td>Phase III – expected Argentina, Germany and NZ during 2013.</td>
</tr>
<tr>
<td>Expected date of filing</td>
<td>Early 2016 in NZ and EU</td>
</tr>
</tbody>
</table>
#3
A major pharmaceutical partner

- Otsuka Pharmaceutical Factory (OPF)
  - Focus on DIABECELL product only

- AUD25m to fund DIABECELL
  - Zero LCT cash burn to move DIABECELL to market

- LCT receives 50% of worldwide profits

- LCT retains exclusive, perpetual license to exploit all IP in all other disease fields
#4
Second product entering clinic in 2013

NTCELL™ for the treatment of Parkinson’s

<table>
<thead>
<tr>
<th>Feature</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product</td>
<td>Encapsulated porcine choroid plexus cells</td>
</tr>
<tr>
<td>Target market</td>
<td>Patients with mid-stage Parkinson’s disease - 1.6m patients</td>
</tr>
<tr>
<td>Product differentiator</td>
<td>Restoration of normal function by regeneration of appropriate neural pathways</td>
</tr>
<tr>
<td>Stage of development</td>
<td>Phase I expected commence in NZ 2013</td>
</tr>
<tr>
<td>Expected date of filing for registration</td>
<td>2018</td>
</tr>
</tbody>
</table>
NTCELL - A powerful mechanism of action
Hundreds of regenerative growth factors & protective agents

New cell formation
Stem cell differentiation
Protection from cell death

TGFβ
IGF-2
NGF
Tty
Anti-Plaque
Anti-Oxidant
SOD
BDNF
EGF
BMPs
#5

NTCELL will be useful in a range of diseases

- Neuro
  - Parkinson's
  - Huntington's
  - Retinopathy
  - Stroke
  - Hearing loss
  - Spinal cord injury

- Musculo-skeletal
  - Osteoarthritis
  - Osteoporosis

- Formulations
  - Wound healing
    - Respiratory diseases

For personal use only
NTCELL will be useful in a range of diseases

Parkinson’s primate

(Lin et al., Regenerative medicine Submitted 2012)

Huntington’s primate


Stroke rat

#5

NTCELL will be useful in a range of diseases

- **Wound healing Rats**
  Thanos et al., Cell Transplantation (2009) 18: 1395-1409

- **Hearing loss - cats**
  Wise et al., Neurotherapeutics (2011) 8:774-787
#6
Sound finances & safe hands

<table>
<thead>
<tr>
<th>Fundamental</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shares outstanding</td>
<td>357m</td>
</tr>
<tr>
<td>5-day VWAP (29/10/12)</td>
<td>0.051</td>
</tr>
<tr>
<td>52 wk Hi/Low</td>
<td>0.13-0.04</td>
</tr>
<tr>
<td>Cash on hand (AUD) (30/9/12)</td>
<td>2.9m</td>
</tr>
<tr>
<td>Current burn/annum (AUD)</td>
<td>1.6m</td>
</tr>
<tr>
<td>Estimate first product revenues</td>
<td>2016</td>
</tr>
</tbody>
</table>

**Board**
- Roy Austin (Chair)
- Professor Bernie Tuch
- Robert Willcocks
- Laurie Hunter
- Professor Bob Elliott

**Management**
- Dr Andrea Grant (CEO)
- Professor Bob Elliott (acting CSMO)
- John Cowan (Finance)
- Peter Hosking (Operations)
- Isobel Cooper (Animal welfare)
SAFE HARBOR STATEMENT

This document contains certain forward-looking statements, relating to LCT’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.